Blu – Pagina 60 – AMD

Blu

Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.

Dicembre 29, 2023 dario.olivero

Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial

Zoungas S, Zhou Z, Owen AJ, et al.
Lancet Diabetes Endocrinol. 2023:S2213-8587(23)00327-3.

Leggi

Dicembre 29, 2023 dario.olivero

Do glycaemic treatment targets affect the perinatal mental health status of women with gestational diabetes? – Data from the TARGET Trial

Ohene-Agyei P, Tran T, Harding JE, Crowther CA
BMC Pregnancy Childbirth. 2023;23(1):869.

Leggi

Dicembre 29, 2023 dario.olivero

Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial

Groenewegen A, Zwartkruis VW, Rienstra M, et al.
Lancet Public Health. 2023:S2468-2667(23)00269-4.

Leggi

Dicembre 21, 2023 dario.olivero

Translating trial results into interpretable risk estimates: systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors

Rizzi A, Kloecker DE, Pitocco D, et al.
NMCD. Pub. online 19 Dec 2023.

Leggi

Dicembre 21, 2023 dario.olivero

Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis

Kobo O, Cavender MA, Jensen TJ, et al.
Diabetes Obes Metab. Pub. online 11 Dec 2023.

Leggi

Dicembre 21, 2023 dario.olivero

Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials

Munshi M, Ritzel R, Jude EB, et al.
Diabetes Obes Metab. Pub. online 11 Dec 2023.

Leggi

Dicembre 21, 2023 dario.olivero

Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial

Wu J, Zhou R, Zhang Q, et al.
Diabetes Obes Metab. Pub. online 15 Dec 2023.

Leggi

Dicembre 21, 2023 dario.olivero

A novel model for predicting diabetes remission after bariatric surgery based on the measurement of C-peptide and creatinine in serum: a pilot study

Colosimo S, Martínez-Sánchez MA, Balaguer-Román A, et al.
NMCD. Pub. online, 16 Dec 2023.

Leggi

Dicembre 14, 2023 dario.olivero

Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy

Cesta CE, Rotem R, Bateman BT, et al.
JAMA Intern Med. 2023:e236663.

Leggi

Dicembre 14, 2023 dario.olivero

Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial

Aronne LJ, Sattar N, Horn DB, et al.
JAMA. 2023:e2324945.

Leggi